Etanercept for ankylosing spondylitis
Record ID 32006001568
English
Authors' objectives:
Etanercept consists of two molecules of the human p75 tumor necrosis factor-alpha (TNF-#) receptor joined to the Fc portion of the human immunoglobulin G1 (IgG1). It binds soluble TNF-# with high specificity and affinity, preventing it from binding to the cell surface receptors (TNF-# receptors) on keratinocytes, thereby inhibiting its proinflammatory effects. Etanercept is prescribed=either alone or in combination with conventional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and nonpharmacologic therapy=to reduce the signs and symptoms of ankylosing spondylitis in adult patients with long-standing active disease, who are refractory to conventional therapy alone.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2006
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=4958
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Immunoglobulin G
- Immunosuppressive Agents
- Receptors, Tumor Necrosis Factor
- Spondylitis, Ankylosing
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
<p>HAYES, Inc.</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.